SRPT Stock: EPS Beats by 190% — Q1 2026 Earnings Analysis

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

SRPT Stock: EPS Beats by 190% — Q1 2026 Earnings Analysis

Listen for free

View show details

About this listen

## Chapters 0:00 The Sarepta Therapeutics Story 3:54 Earnings Overview Sarepta Therapeutics just reported Q1 2026 earnings — eps beats by 190%. Here's what the double beat means for SRPT and whether the bull case is playing out. 🔔 Subscribe for weekly deep dives on every Russell 1000 earnings report: https://www.youtube.com/@ChargedAlpha?sub_confirmation=1 📊 Key Financial Highlights: • Revenue: $731M vs $476M expected (+53.5% beat) • EPS: $3.16 vs $1.09 expected (+189.9% beat) 📈 Free stock screening tools — no signup, no paywall: https://chargedalpha.com 🎧 Also available as a podcast: https://chargedalpha.podbean.com #stocks #SRPT #earnings #stocks #investing #stockmarket #earningsseason #wallstreet #SareptaTherapeutics --- Financial data and charts: Financial Modeling Prep (https://financialmodelingprep.com) ⚖️ Disclaimer: This video is for informational and educational purposes only. Nothing discussed constitutes a buy, sell, or hold recommendation. All investments carry risk. Past performance does not guarantee future results. Always do your own research and consult a qualified financial advisor. Hosts may hold positions in securities discussed. This episode was researched, written, and produced using AI-assisted tools. Data sourced from public filings and may contain inaccuracies. Watch on YouTube: https://www.youtube.com/watch?v=YKDsVAZnKwQ

No reviews yet